RATIONALE: Manipulations of the endocannabinoid/fatty acid amide hydrolase (FAAH) signaling systems result in conflicting and paradoxical effects in rodent models of emotional reactivity. OBJECTIVES: In the present study, we tested the hypothesis that the inhibition of FAAH would elicit significant effects in murine models used to screen anxiolytic and antidepressant drugs. MATERIALS AND METHODS: FAAH (-/-) mice and wild-type mice treated with FAAH inhibitors (URB597 and OL-135) were evaluated in standard behavioral screening models for antidepressant (i.e., tail suspension and forced-swim tests) and anxiolytic (i.e., elevated plus maze) agents. The doses of URB597 and OL-135 selected were based on their ability to augment the pharmacological effects (i.e., analgesia, catalepsy, and hypothermia) of exogenously administered anandamide. RESULTS: FAAH (-/-) mice, anandamide-injected FAAH (-/-) mice, or wild-type mice injected with FAAH inhibitors or anandamide failed to exhibit significant effects in standard tests of emotional reactivity, although the antidepressant desipramine and the anxiolytic agent midazolam were active in the appropriate assays. FAAH- (-/-) and URB597-treated mice finally displayed significant effects in the tail suspension test when substantial methodological changes were made (i.e., altered ambient light and increased sample sizes). CONCLUSIONS: Although FAAH suppression can elicit significant effects under some instances in which consequential procedural modifications are made, the present results indicate that the pharmacological inhibition or genetic deletion of FAAH is ineffective in standard mouse models of emotional reactivity. It remains to be established whether the effects of FAAH inhibition in these modified tasks are predictive of their efficacy in treating emotional disorders.
RATIONALE: Manipulations of the endocannabinoid/fatty acid amide hydrolase (FAAH) signaling systems result in conflicting and paradoxical effects in rodent models of emotional reactivity. OBJECTIVES: In the present study, we tested the hypothesis that the inhibition of FAAH would elicit significant effects in murine models used to screen anxiolytic and antidepressant drugs. MATERIALS AND METHODS: FAAH (-/-) mice and wild-type mice treated with FAAH inhibitors (URB597 and OL-135) were evaluated in standard behavioral screening models for antidepressant (i.e., tail suspension and forced-swim tests) and anxiolytic (i.e., elevated plus maze) agents. The doses of URB597 and OL-135 selected were based on their ability to augment the pharmacological effects (i.e., analgesia, catalepsy, and hypothermia) of exogenously administered anandamide. RESULTS: FAAH (-/-) mice, anandamide-injected FAAH (-/-) mice, or wild-type mice injected with FAAH inhibitors or anandamide failed to exhibit significant effects in standard tests of emotional reactivity, although the antidepressant desipramine and the anxiolytic agent midazolam were active in the appropriate assays. FAAH- (-/-) and URB597-treated mice finally displayed significant effects in the tail suspension test when substantial methodological changes were made (i.e., altered ambient light and increased sample sizes). CONCLUSIONS: Although FAAH suppression can elicit significant effects under some instances in which consequential procedural modifications are made, the present results indicate that the pharmacological inhibition or genetic deletion of FAAH is ineffective in standard mouse models of emotional reactivity. It remains to be established whether the effects of FAAH inhibition in these modified tasks are predictive of their efficacy in treating emotional disorders.
Authors: Satish Kathuria; Silvana Gaetani; Darren Fegley; Fernando Valiño; Andrea Duranti; Andrea Tontini; Marco Mor; Giorgio Tarzia; Giovanna La Rana; Antonio Calignano; Arcangela Giustino; Maria Tattoli; Maura Palmery; Vincenzo Cuomo; Daniele Piomelli Journal: Nat Med Date: 2002-12-02 Impact factor: 53.440
Authors: L Steru; R Chermat; B Thierry; J A Mico; A Lenegre; M Steru; P Simon; R D Porsolt Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 1987 Impact factor: 5.067
Authors: G Gobbi; F R Bambico; R Mangieri; M Bortolato; P Campolongo; M Solinas; T Cassano; M G Morgese; G Debonnel; A Duranti; A Tontini; G Tarzia; M Mor; V Trezza; S R Goldberg; V Cuomo; D Piomelli Journal: Proc Natl Acad Sci U S A Date: 2005-12-13 Impact factor: 11.205
Authors: Dale L Boger; Hiroshi Miyauchi; Wu Du; Christophe Hardouin; Robert A Fecik; Heng Cheng; Inkyu Hwang; Michael P Hedrick; Donmienne Leung; Orlando Acevedo; Cristiano R W Guimarães; William L Jorgensen; Benjamin F Cravatt Journal: J Med Chem Date: 2005-03-24 Impact factor: 7.446
Authors: M N Hill; S A Kumar; S B Filipski; M Iverson; K L Stuhr; J M Keith; B F Cravatt; C J Hillard; S Chattarji; B S McEwen Journal: Mol Psychiatry Date: 2012-07-10 Impact factor: 15.992
Authors: Mason M Silveira; Jonathon C Arnold; Steven R Laviolette; Cecilia J Hillard; Marta Celorrio; María S Aymerich; Wendy K Adams Journal: Neurosci Biobehav Rev Date: 2016-09-14 Impact factor: 8.989
Authors: Sachin Patel; Mathew N Hill; Joseph F Cheer; Carsten T Wotjak; Andrew Holmes Journal: Neurosci Biobehav Rev Date: 2017-05 Impact factor: 8.989